BW 01
Alternative Names: BW-01Latest Information Update: 07 Feb 2024
At a glance
- Originator Argo Biopharma
- Class Cardiovascular therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Cardiovascular disorders
Most Recent Events
- 07 Feb 2024 BW 01 is available for licensing as of 07 Feb 2024. https://www.argobiopharma.com/partnering/index.html (Aargo Biopharma website January 2024)
- 31 Jan 2024 Argo Biopharma and Novartis agree to co-promote BW 01 for Cardiovascular disorders
- 31 Jan 2024 Argo Biopharma completes phase-I clinical trials in Cardiovascular disorders in Australia (SC)